{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["129(3)"],"submitter":["Thavaneswaran S"],"funding":["OHMR - Health Administration Corporation as represented by the Ministry of Health Commonwealth Government Grant (GO 1964) MRFF Emerging Priorities and Consumer Driven Research initiative"],"pubmed_abstract":["<h4>Purpose</h4>To determine the safety and efficacy of PARP plus PD-L1 inhibition (olaparib + durvalumab, O + D) in patients with advanced solid, predominantly rare cancers harbouring homologous recombination repair (HRR) defects.<h4>Patients and methods</h4>In total, 48 patients were treated with O + D, 16 with BRCA1/2 alterations (group 1) and 32 with other select HRR alterations (group 2). Overall, 32 (66%) patients had rare or less common cancers. The primary objective of this single-arm Phase II trial was a progression-free survival rate at 6 months (PFS6). Post hoc exploratory analyses were conducted on archival tumour tissue and serial bloods.<h4>Results</h4>The PFS6 rate was 35% and 38% with durable objective tumour responses (OTR) in 3(19%) and 3(9%) in groups 1 and 2, respective"],"journal":["British journal of cancer"],"pagination":["475-485"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10403555"],"repository":["biostudies-literature"],"pubmed_title":["A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations."],"pmcid":["PMC10403555"],"pubmed_authors":["Mundra P","Grady JP","Schmitz U","Sebastian L","Joshua AM","Thomas DM","Simes J","Corpuz T","Lee CK","Ballinger ML","Espinoza D","Kansara M","Lin F","Thavaneswaran S","Bailey CG","Qiu MR"],"additional_accession":[]},"is_claimable":false,"name":"A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations.","description":"<h4>Purpose</h4>To determine the safety and efficacy of PARP plus PD-L1 inhibition (olaparib + durvalumab, O + D) in patients with advanced solid, predominantly rare cancers harbouring homologous recombination repair (HRR) defects.<h4>Patients and methods</h4>In total, 48 patients were treated with O + D, 16 with BRCA1/2 alterations (group 1) and 32 with other select HRR alterations (group 2). Overall, 32 (66%) patients had rare or less common cancers. The primary objective of this single-arm Phase II trial was a progression-free survival rate at 6 months (PFS6). Post hoc exploratory analyses were conducted on archival tumour tissue and serial bloods.<h4>Results</h4>The PFS6 rate was 35% and 38% with durable objective tumour responses (OTR) in 3(19%) and 3(9%) in groups 1 and 2, respective","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Aug","modification":"2025-04-05T00:24:14.486Z","creation":"2025-04-05T00:24:14.486Z"},"accession":"S-EPMC10403555","cross_references":{"pubmed":["37365284"],"doi":["10.1038/s41416-023-02311-0"]}}